The goal of this study is to preliminarily determine/estimate feasibility and whether frequent and early conivaptan use, at a dose currently determined to be safe (i.e., 40mg/day), is safe and well-tolerated in patients with cerebral edema from intracerebral hemorrhage (ICH) and pressure (ICP). A further goal is to preliminarily estimate whether conivaptan at this same dose can reduce cerebral edema (CE) in these same patients. This study is also an essential first step in understanding the role of conivaptan in CE management.
Hypothesis: The frequent and early use of conivaptan at 40mg/day will be safe and well-tolerated, and also reduce cerebral edema, in patients with intracerebral hemorrhage and pressure.

Start Date22 Mar 2017

Sponsor / Collaborator

Allina Health System, Inc.

NCT01954290

/ WithdrawnPhase 2IIT

Treatment of Brain Edema and Herniation Secondary to Ischemic or Hemorrhagic Stroke

Stroke remains the fourth leading cause of death in the United States (second worldwide) and a leading cause of long-term disability, resulting in total direct and indirect costs of approximately $73.7 billion annually. The failure of novel therapies in clinical trials demonstrates that the complex neural response to stroke must be targeted at multiple levels to improve patient outcomes. Despite significant improvements in stroke treatment and management, 1 year survival rate among stroke patients aged 65 years or more is around 25%, and 5- year survival rate amounts to approximately 50%. The highest chances of death are within 30 days of stroke. Mortality increases due to worsening brain dysfunction, elevated intracranial pressure (ICP), and other comorbid conditions.
Treatments aimed at reducing post-stroke cytotoxic edema may reduce the risk for development of malignant stroke and mortality. Current treatments such as osmo-therapy and hemicraniectomy have substantial limitations, and mortality remains high, despite these measures outcomes remain unsatisfactory. There is a great need for alternative medical approaches which are safe, predictable, and help to ameliorate post stroke edema.

Start Date01 Sep 2015

Sponsor / Collaborator

University of Florida

NCT01752543

/ CompletedPhase 4IIT

Effects on Exercise Hemodynamics of Vasopressin Blockade by Conivaptan Infusion in Heart Failure Patients

The purpose of the present study is to evaluate the effects of a blockade of the vasopressin system and central hemodynamic system in heart failure (HF) patients during physical exercise. The significance of the vasopressin system during physical exercise is unclear. If vasopressin is a significant regulator of exercise hemodynamics in HF, strategies to intervene against activation of the V1A-receptor might be expected to improve HF symptoms and possibly outcome.
The potential effects of the central hemodynamic system will be evaluated with a Swan-Ganz catheter. Echocardiography will be performed at rest and during submaximal working capacity before and during the infusion of a vasopressin receptor antagonist (conivaptan) or placebo. Cardiac output will be measured by thermodilution. The exercise test will be performed at 50 % of VO2 max and hemodynamic and echocardiographic measurements will be collected. The exercise test will be performed on a supine multistage bicycle.

Start Date01 Dec 2013

Sponsor / Collaborator

Rigshospitalet

[+1]

100 Clinical Results associated with Conivaptan Hydrochloride

100 Translational Medicine associated with Conivaptan Hydrochloride

100 Patents (Medical) associated with Conivaptan Hydrochloride

317

Literatures (Medical) associated with Conivaptan Hydrochloride

01 Sep 2026·JOURNAL OF NEUROENDOCRINOLOGY

A symmetric systemic challenge elicits a right‐biased response mediated by vasopressin signaling

Article

Author: Schouenborg, Jens ; Hallberg, Mathias ; Mohamed, Sara Yusuf ; Kobikov, Yaromir ; Rich, Karen ; Zhang, Mengliang ; Grönbladh, Alfhild ; Watanabe, Hiroyuki ; Sarkisyan, Daniil ; Bakalkin, Georgy ; Nosova, Olga

Abstract:

Bilaterian animals exhibit functional asymmetry—population‐level, directional left–right differences in physiology and behavior, including responses to spatially symmetric environmental challenges. Whether such symmetry‐to‐asymmetry conversion can be driven at the systems level by neurohormonal regulators remains unclear. Here we tested whether a spatially symmetric neuroendocrine challenge—water deprivation (WD)—can elicit a directional left–right physiological response in rats using hindlimb postural asymmetry (HL‐PA), a binary readout that quantifies left‐ versus right‐sided hindlimb flexion. Twenty‐four hours of WD induced robust HL‐PA with right hindlimb flexion, revealed under anesthesia. The asymmetry persisted after complete thoracic spinal cord transection, suggesting that humoral signaling, rather than descending neural commands, maintains the postural bias. Dehydration activated the hypothalamic arginine vasopressin (AVP) system. Furthermore, a V1B antagonist (SSR‐149415) and a V1A/V2 antagonist (conivaptan) abolished and partially attenuated WD‐induced HL‐PA, respectively, supporting an AVP‐dependent mechanism that likely operates at least two anatomical sites. AVP signaling may involve pituitary V1B‐dependent endocrine output and spinal V1A actions; consistent with the latter, expression of AVP V1A receptors is right‐biased in lumbar spinal cord. Together, these findings identify WD as a symmetric systemic challenge capable of unmasking a directional peripheral bias and implicate vasopressin signaling in left–right physiological regulation. More broadly, they suggest that symmetric homeostatic challenges engage neuroendocrine mechanisms that shift the balance between left‐ and right‐sided physiological functions.

01 Mar 2026·Computational and Structural Biotechnology Journal

Knowledge Discovery and Drug-Repurposing Framework for Pancreatic Ductal Adenocarcinoma: Molecular Networking and Computational Docking

Article

Author: Zhao, Chun-Mei ; Corbo, Tarik ; Graarud, Elisabeth Pimpisa ; Chen, Duan ; Pojskic, Naris ; Resell, Mathilde ; Kalajdzic, Abdurahim ; Gustafsson, Björn I.

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, driven by profound molecular heterogeneity and resistance to current therapy. To support systematic target identification, we established a proteomics-anchored knowledge discovery framework integrating cross-model proteomics harmonization, network topology, high-confidence structural modeling, and large-scale in silico docking. From 1,975 proteins consistently detected across murine and human PDAC models, 32 immunohistochemically confirmed candidates were prioritized for structure-based screening against 7,509 clinically characterized compounds. Blind docking, refined pose sampling, ligand-efficiency scoring, and ADME filtering identified EIF2A, STAM, ANXA2, and AHNAK2 as robustly druggable targets. These proteins exhibited high-affinity interactions with zavegepant (a clinically approved CGRP receptor antagonist), omilancor, bemcentinib, conivaptan, and APTO-253. Docking validation (RMSD 1.98 to 2.56 Å) confirmed methodological reliability, and network analyses placed the 4 proteins within modules linked to endosomal/membrane trafficking and invasive phenotypes. Survival analyses in 176 PDAC patients further supported their clinical relevance. Thus, we suggest a systems-level platform for nominating ligandable PDAC targets and clinically actionable compounds. The framework highlights opportunities for rational drug repurposing and motivates future mechanistic studies at the intersection of proteomics and structure-based screening for targets to PDAC.

12 Dec 2025·JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS

Identification of high-affinity inhibitors for epoxide hydrolase 2 from repurposed drugs in Parkinson’s disease therapeutics

Article

Author: Asimul Islam ; Dharmendra Kumar Yadav ; Moyad Shahwan ; Sohaib Naseem Khan ; Anas Shamsi ; Mohd Shahnawaz Khan ; Nojood Altwaijry

Parkinson's disease (PD) is a prevalent neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra that leads to bradykinesia and rest tremors. While the molecular mechanisms underlying PD are not fully understood, rising evidence shows neuroinflammation as a key factor in dopaminergic neuron damage. The soluble epoxide hydrolase (sEH) has appeared as a key player in neuroinflammation associated with PD which represents itself as a promising drug target. Here, we employed a structure-based virtual screening methodology using repurposed drugs from the DrugBank database to identify high-affinity potential inhibitors of sEH. Results showed that two hit molecules, Fluspirilene and Penfluridol, demonstrated appreciable docking potential and specificity toward the sEH active site. These molecules exhibited favorable pharmacological properties and formed critical interactions with residues essential for sEH activity. Further, all-atom molecular dynamics (MD) simulations followed by principal component analysis and free energy landscape were carried out which provide deeper insights into the conformational stability and interaction mechanisms of sEH in complex with Fluspirilene and Penfluridol. The simulation results indicated that the interaction of sEH with Fluspirilene and Penfluridol contributed to the stabilization of its structure throughout the MD trajectories of 500 ns. These findings collectively suggest that Fluspirilene and Penfluridol hold potential as repurposed leads for the development of sEH inhibitors, which offer therapeutic implications for combating PD and other associated conditions.

News (Medical) associated with Conivaptan Hydrochloride

01 Jul 2026

·www.apotex.com

Apotex completes previously announced strategic transaction with Cumberland Pharmaceuticals

TORONTO, July 1, 2026 /CNW/ – Apotex Health Corp. ("Apotex") (TSX: APTX), the largest Canadian-based pharmaceutical company, today announced the closing of its previously announced strategic transaction with Cumberland Pharmaceuticals Inc. ("Cumberland"), a U.S. biopharmaceutical company, to integrate Cumberland's U.S. branded businesses into Apotex. With the completion of the strategic transaction, Apotex adds a portfolio of established branded medicines to its U.S. business, expanding its specialty and hospital-focused presence across key therapeutic areas including acute care, oncology, infectious disease, and gastroenterology. "This milestone strengthens our ability to support patients and healthcare providers across the United States," said Jeff Watson, President & CEO of Apotex. "We look forward to integrating these important medicines into our portfolio and expanding access to high-quality treatments." "We are pleased to have completed this strategic transaction with Apotex, which will create more critical mass to better support patient care," said A.J. Kazimi, CEO of Cumberland Pharmaceuticals. The portfolio includes well-established brands, including Kristalose®, Caldolor®, Sancuso®, Vibativ®, Acetadote®, Vaprisol®, and Talicia®, which are prescribed across hospitals, oncology, infectious disease, and gastroenterology settings. About Apotex Apotex is a Canadian-based global health company. We improve everyday access to affordable, innovative medicines and health products for millions of people around the world, with a broad portfolio of generic, biosimilar, and innovative branded pharmaceuticals, and consumer health products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico, and India, we are the largest Canadian-based pharmaceutical company and a health partner of choice for the Americas for pharmaceutical licensing and product acquisitions. Learn more at www.apotex.com Forward-Looking Statements This press release may contain forward-looking information within the meaning of applicable securities laws, including statements about strengthening Apotex's ability to support patients and healthcare providers across the United States, Apotex integrating the acquired medicines into its portfolio and expanding access to high-quality treatments, and creating critical mass to better support patient care. Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates and projections regarding future events or circumstances. Forward-looking information is necessarily based on a number of opinions, estimates and assumptions that, while considered by Apotex to be appropriate and reasonable as of the date of this release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause actual results to differ materially from those expressed or implied by such forward-looking information. Such risks and uncertainties include, but are not limited to, factors discussed under “Risk Factors” in Apotex's public filings and include risks associated with Apotex being unable to support patients and healthcare providers across the United States, failure to integrate the acquired medicines in Apotex's portfolio, failure to expand access to high-quality treatments and failure to create critical mass to better support patient care. Apotex undertakes no obligation to publicly update or review any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required under applicable securities laws. About Cumberland Pharmaceuticals Cumberland Pharmaceuticals Inc. is a Nashville-based biopharmaceutical company focused on developing new therapies for rare diseases. The company is advancing a late-stage pipeline of product candidates through a series of late-stage clinical studies. The treatments are being developed across multiple therapeutic areas to address serious patient conditions that represent unmet medical needs. Cumberland's Phase 2 clinical programs are evaluating ifetroban in patients with Duchenne Muscular Dystrophy, Systemic Sclerosis, Idiopathic Pulmonary Fibrosis and Cancer Metastasis. For more information, please visit www.cumberlandpharma.com Media contact: media@apotex.com

Phase 2Acquisition

05 May 2026

·www.prnewswire.com

CUMBERLAND PHARMACEUTICALS REPORTS Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE

Enters into Strategic Transaction, unlocking $100 million in value Sharpens focus on Orphan Drug candidates to address unmet medical needs NASHVILLE, Tenn., May 5, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $9.1 million during the first quarter of 2026. Cumberland ended the quarter with $71.0 million in total assets, $49.7 million in liabilities and $21.6 million of shareholders' equity. "We entered 2026 with strong momentum following an outstanding 2025, which featured double-digit revenue growth, the addition of a new product to our portfolio, new international approvals and breakthrough clinical study results," said A.J. Kazimi, Cumberland Pharmaceuticals CEO. "We have built on that momentum through our recently announced Strategic Transaction, which represents an important next step in our Company's evolution, enabling us to sharpen our focus on developing high-value product candidates, while unlocking significant value for our shareholders." RECENT COMPANY DEVELOPMENTS INCLUDE: Strategic Transaction Cumberland recently announced a Strategic Transaction with Apotex Inc., the largest Canadian-based pharmaceutical company, to integrate the branded U.S. commercial businesses. Under the terms of the agreement, Apotex will acquire Cumberland's portfolio of FDA-approved brands for $100 million in cash consideration, subject to Cumberland shareholders' approval and certain other customary closing conditions. This transaction is designed to unlock value and sharpen Cumberland's focus on advancing its pipeline of differentiated product candidates designed to address unmet medical needs. The integration of Cumberland's products will create more critical mass to support patient care and expand product distribution. Following the closing of the transaction, Cumberland will retain its development programs, as well as its majority ownership in Cumberland Emerging Technologies. This positions Cumberland to operate with the profile of an innovative, development-stage biopharmaceutical organization devoted to new medicines for the future. Development Pipeline In addition to its portfolio of FDA-approved brands involved in the transaction with Apotex, Cumberland is developing ifetroban, a potent thromboxane antagonist, through a series of clinical programs designed to address unmet medical needs with significant market potential. Cumberland has announced breakthrough results in a Phase II clinical study of ifetroban in patients with cardiomyopathy associated with Duchenne muscular dystrophy ("DMD"). This rare, fatal genetic neuromuscular disease results in deterioration of the skeletal, heart and lung muscles. Discussions with the FDA are underway regarding the study results and remaining requirements for approval. During the first quarter of 2026, the FDA granted Fast Track Designation for Cumberland's ifetroban candidate product for DMD patients. This designation is intended to accelerate the development and review of therapies that address serious conditions with unmet medical needs. Importantly, it allows for more frequent FDA interaction, rolling data submissions and earlier guidance throughout the approval process. The program previously received both Orphan Drug and Rare Pediatric Disease designations from the FDA. In addition, Cumberland has a Phase II clinical program evaluating its ifetroban product candidate in patients with Systemic Sclerosis ("SSc") or scleroderma, a debilitating autoimmune disorder characterized by diffuse fibrosis of the skin and internal organs. Enrollment in the study is completed and the next milestone will be announcing its top-line study results. Cumberland's third development program involves the use of ifetroban in patients with Idiopathic Pulmonary Fibrosis ("IPF"), the most common form of progressive fibrosing interstitial lung disease. Enrollment in the study is well underway at medical centers across the U.S., with interim safety and interim efficacy results pending. FINANCIAL RESULTS: Net Revenue: For first quarter of 2026, the Company's net revenues of $9.1 million, which represented a 5% increase compared to the first quarter of 2025 after removing the $3 million milestone payment last year associated with the approval of Vibativ® in China. Cumberland's branded portfolio revenue included $1.0 million for Kristalose®, $2.9 million for Sancuso®, $2.1 million for Vibativ®, $1.0 million for Caldolor® and $1.9 million for Talicia.® Operating Expenses: Total operating expenses for the quarter were $12.3 million. Net Income (Loss): The net loss for the first quarter of 2026 was approximately $3.3 million. Adjusted Earnings (Loss): Adjusted loss for the quarter was $1.9 million, or $0.13 per share. Balance Sheet: At March 31, 2026, Cumberland had approximately $71.0 million in total assets, including $11.0 million in cash and cash equivalents. Liabilities totaled $49.7 million, including $5.2 million on the company's credit facility. Total shareholders' equity was $21.6 million on March 31, 2026. EARNINGS REPORT CALL: A conference call will be held today, May 5, 2026, at 4:30 p.m. Eastern Time to provide a company update and discuss the financial results. The link to register is . Registered participants can dial in from their phone using a dial-in and PIN number that will be provided to them. Alternatively, they can choose a "Call Me" option to have the system automatically call them at the start of the conference. A replay of the call will be available for one year and can be accessed via Cumberland's website or by visiting: . ABOUT CUMBERLAND PHARMACEUTICALS: Cumberland Pharmaceuticals Inc. is the largest biopharmaceutical company founded and headquartered in Tennessee and is focused on providing unique products that improve the quality of patient care. The company develops, acquires, and commercializes products for the hospital acute care, gastroenterology and oncology market segments. The company's portfolio of FDA-approved brands includes: Acetadote ® (acetylcysteine) injection, for the treatment of acetaminophen poisoning; Caldolor ® (ibuprofen) injection, for the treatment of pain and fever; Kristalose ® (lactulose) oral, a prescription laxative, for the treatment of constipation; Sancuso ® (granisetron) transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisol ® (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ ® (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and Talicia ® (omeprazole, amoxicillin and rifabutin) oral capsule, for the treatment of H. pylori infection. The company also has a series of Phase II clinical programs underway evaluating its ifetroban product candidate in patients with Duchenne Muscular Dystrophy, Systemic Sclerosis and Pulmonary Fibrosis. For more information on Cumberland's approved products, including full prescribing information, please visit the links to the individual product websites, which can be found on the company's website at . About Acetadote ® (acetylcysteine) Injection Acetadote, administered intravenously within 8 to 10 hours after ingestion of a potentially hepatotoxic quantity of acetaminophen, is indicated to prevent or lessen hepatic injury. Used in the emergency department, Acetadote is approved in the United States to treat overdose of acetaminophen, a common ingredient in many over-the-counter medications. Acetadote is contraindicated in patients with hypersensitivity or previous anaphylactoid reactions to acetylcysteine or any components of the preparation. For full prescribing and safety information, visit . About Caldolor ® (ibuprofen) Injection Caldolor is indicated in adults and pediatric patients for the management of mild to moderate pain and the management of moderate to severe pain as an adjunct to opioid analgesics, as well as the reduction of fever. It was the first FDA-approved intravenous therapy for fever. Caldolor is contraindicated in patients with known hypersensitivity to ibuprofen or other non-steroidal anti-inflammatory drugs (NSAIDs) as well as patients with a history of asthma or other allergic type reactions after taking aspirin or other NSAIDs. Caldolor is contraindicated for use during the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery. For full prescribing and safety information, including boxed warning, visit . About Kristalose ® (lactulose) Oral Solution Kristalose is indicated for the treatment of acute and chronic constipation. It is a unique, proprietary, crystalline form of lactulose, with no restrictions on length of therapy or patient age. Kristalose is contraindicated in patients who require a low-galactose diet. Elderly, debilitated patients who receive lactulose for more than six months should have serum electrolytes (potassium, chloride, carbon dioxide) measured periodically. For full prescribing and safety information, visit . About Sancuso ® ( granisetron) Transdermal System Sancuso is the only skin patch approved by the FDA for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately and/or highly emetogenic chemotherapy. When applied 24 to 48 hours before receiving chemotherapy, the Sancuso patch slowly and continuously releases the medicine contained in the adhesive through clean and intact skin areas into the patient's bloodstream. It can prevent CINV for chemotherapy regimens of up to five consecutive days. For full prescribing and safety information, visit . About Vaprisol ® (conivaptan hydrochloride) Injection Vaprisol is an intravenous treatment for hyponatremia used in the critical care setting. Hyponatremia is an electrolyte disturbance in which sodium ion concentration in blood plasma is lower than normal. This can be associated with a variety of critical care conditions including congestive heart failure, liver failure, kidney failure and pneumonia. The product is a vasopressin receptor antagonist that raises serum sodium levels and promotes free water secretion. Vaprisol is contraindicated in patients with hypovolemic hyponatremia. The coadministration of Vaprisol with potent CYP3A inhibitors, such as ketoconazole, itraconazole, clarithromycin, ritonavir and indinavir, is contraindicated. For full prescribing and safety information, including boxed warning, visit . About Vibativ ® (telavancin) for Injection Vibativ is a patented, FDA-approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant. Intravenous unfractionated heparin sodium is contraindicated with Vibativ administration due to artificially prolonged activated partial thromboplastin time (aPTT) test results for up to 18 hours after Vibativ administration. Vibativ is contraindicated in patients with a known hypersensitivity to telavancin. For more information, please visit . About Talicia ® Talicia® is an FDA approved oral capsule for the treatment of Helicobacter pylori (H. pylori) infection in adults, a bacterial infection of the stomach and leading risk factor for gastric cancer. Talicia is listed as a first line option in the 2024 ACG Guideline for the treatment of H. pylori and features three key advantages: 1) high eradication rates - >90% in confirmed adherent patients, 2) the simplicity of an all-in-one capsule, and 3) low resistance to the two antibiotics - amoxicillin and rifabutin. For more information, please visit . FORWARD LOOKING STATEMENTS: This press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland's current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. Forward-looking statements include, among other things, statements regarding the Company's intent, belief or expectations, and can be identified by the use of terminology such as "may," "will," "expect," "believe," "intend," "plan," "estimate," "goal", "should," "seek," "anticipate," "look forward" and other comparable terms or the negative thereof. As with any business, all phases of Cumberland's operations are subject to factors outside of its control, and any one or combination of these factors could materially affect Cumberland's operation results. These factors include risks and uncertainties related to the strategic transaction, risks related to our ability to develop our pipeline of new product candidates, macroeconomic conditions, including changes in interest rates, inflation, tariffs, competition, an inability of manufacturers to produce Cumberland's products on a timely basis, failure of manufacturers to comply with regulations applicable to pharmaceutical manufacturers, natural disasters, public health epidemics, maintaining an effective sales and marketing infrastructure, and other events beyond the Company's control as more fully discussed in its most recent annual report on Form 10-K as filed with the U.S. Securities and Exchange Commission ("SEC"), as well as the Company's other filings with the SEC from time to time. There can be no assurance that results anticipated by the company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof. The Company provided the above adjusted supplemental financial performance measures, which are considered "non-GAAP" financial measures under applicable SEC rules and regulations. These financial measures should be considered supplemental to, and not as a substitute for, financial information prepared in accordance with Generally Accepted Accounting Principles ("GAAP"). The definition of these supplemental measures may differ from similarly titled measures used by others. Because these supplemental financial measures exclude the effect of items that will increase or decrease the Company's reported results of operations, management encourages investors to review the Company's consolidated financial statements and publicly filed reports in their entirety. A reconciliation of the supplemental financial measures to the most directly comparable GAAP financial measures is included in the tables accompanying this release. Cumberland's management believes these supplemental financial performance measures are important as they are used by management, along with financial measures in accordance with GAAP, to evaluate the Company's operating performance. In addition, Cumberland believes that they will be used by certain investors to measure the Company's operating results. Management believes that presenting these supplemental measures provides useful information about the Company's underlying performance across reporting periods on a consistent basis by excluding items that Cumberland does not believe are indicative of its core business performance or reflect long-term strategic activities. Certain of these items are not settled through cash payments and include: depreciation, amortization of intangible and right-of-use assets, share-based compensation expense and income taxes. Cumberland utilizes its net operating loss carryforwards to pay minimal income taxes. In addition, the use of these financial measures provides greater transparency to investors of supplemental information used by management in its financial and operational decision-making, including the evaluation of the Company's operating performance. The Company defines these supplemental financial measures as follows: Adjusted Earnings (loss): Net income (loss) adjusted for the impact of income taxes, depreciation and amortization expense, share-based compensation, interest income and interest expense. (a) Represents the share-based compensation of Cumberland. (b) Represents the straight line reduction in carrying value of right-of-use assets. Adjusted Diluted Earnings (loss) Per Share: Adjusted Earnings (loss) divided by diluted weighted-average common shares outstanding. SOURCE Cumberland Pharmaceuticals Inc. 21% more press release views with Request a Demo

Phase 2Drug ApprovalOrphan DrugAcquisitionFast Track

28 Apr 2026

·www.prnewswire.com

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE

NASHVILLE, Tenn., April 28, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its first quarter 2026 financial results and provide a company update after the market closes on Tuesday, May 5, 2026. A conference call will be held on May 5 at 4:30 p.m. Eastern Time to discuss the results and update. The link to register is . Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them. Alternatively, they can choose a "Call Me" option to have the system automatically call them at the start of the conference. A replay of the call will be available for one year and can be accessed via the Investor Relations page of Cumberland's website or by visiting . Cumberland Pharmaceuticals is a specialty pharmaceutical company dedicated to providing unique products that improve patient care. The company develops, acquires, and commercializes products for the hospital acute care, gastroenterology and oncology market segments. The company's portfolio of FDA-approved brands includes: Acetadote ® (acetylcysteine) injection, for the treatment of acetaminophen poisoning; Caldolor ® (ibuprofen) injection, for the treatment of pain and fever; Kristalose ® (lactulose) for oral solution, a prescription laxative, for the treatment of constipation; Sancuso ® (granisetron) transdermal system, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisol ® (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ ® (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and Talicia ® (omeprazole, amoxicillin and rifabutin) oral capsule, for the treatment of H. pylori infection. The Company also has a series of Phase II clinical programs underway evaluating its ifetroban product candidate in patients with Systemic Sclerosis, the cardiomyopathy associated with Duchenne Muscular Dystrophy and Idiopathic Pulmonary Fibrosis. For more information on Cumberland's approved products, including full prescribing information, please visit links to the individual product websites, found on the company's website at . SOURCE Cumberland Pharmaceuticals Inc. 21% more press release views with Request a Demo

Phase 2Drug ApprovalFinancial Statement

100 Deals associated with Conivaptan Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D01236	Conivaptan Hydrochloride	C03XA02	DB00872

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Heart Failure	United States	Apotex, Inc.	29 Dec 2005
Hyponatremia	United States	Apotex, Inc.	29 Dec 2005

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute decompensated heart failure	Phase 3	India	Cumberland Pharmaceuticals, Inc.	01 Apr 2009
Chronic hyponatremia	Phase 2	China	Beijing Furuikangzheng Medicine Technology Research Institute	28 Aug 2018
Chronic hyponatremia	Phase 2	China	Jiangsu Vanguard Pharmaceutical Co., Ltd.	28 Aug 2018
Water Intoxication	Phase 2	China	Jiangsu Vanguard Pharmaceutical Co., Ltd.	28 Aug 2018
Water Intoxication	Phase 2	China	Beijing Furuikangzheng Medicine Technology Research Institute	28 Aug 2018
Chronic heart failure	Phase 2	United States	Cumberland Pharmaceuticals, Inc.	01 Nov 2002
Decompensated chronic heart failure	Phase 2	United States	Cumberland Pharmaceuticals, Inc.	01 Nov 2002
Kidney Diseases	Phase 1	United States	Cumberland Pharmaceuticals, Inc.	01 Apr 2009
Chronic congestive heart failure	Clinical	United States	Astellas Pharma, Inc.	01 Jul 2009
Melioidosis	Preclinical	India	Indian Institute of Technology Kharagpur	18 May 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03000283 (CTgov)	Phase 1	Cerebral Hemorrhage \| Stroke \| Brain Edema	7	Conivaptan	pmhuetkhgm = emygvbfatu voxlwaypcy (fyufmitunv, exrwrlepke - vfyyrtghjn) View more	-	17 Apr 2020
NCT01451411 (CTgov)	Phase 3	Hyponatremia	4	Conivaptan hydrochloride (Conivaptan Hydrochloride)	qzrtcqarsf(tpeztxlpim) = cdyhdckjnc rcdrcxqzvw (wxbnrfzzoh, 5.3) View more	-	01 Mar 2016
				Placebo (Placebo)	qzrtcqarsf(tpeztxlpim) = yfqigpsrmp rcdrcxqzvw View more
NCT00843986 (CONVERT-H, CTgov)	Phase 3	Hyponatremia \| Acute decompensated heart failure	9	placebo (Placebo)	tocgewohpi(aznetpmsjg) = srwyasvmts tdbouqlkdf (izkpdldjsi, jogkzsgvzi - twdjypjkyf) View more	-	01 Oct 2010
				conivaptan (Conivaptan)	tocgewohpi(aznetpmsjg) = lxiwowigny tdbouqlkdf (izkpdldjsi, xxswsklfxz - euvzrkzidf) View more
NCT00592475 (CTgov)	Phase 2	Liver Cirrhosis	20	conivaptan (Regimen 1 Conivaptan 12.5 mg)	wekhqgurld(ddnzvcdsce) = wapkcxtfcq taoaoonubc (mxlbfnpucw, 4.375) View more	-	28 Sep 2010
				conivaptan (Regimen 2 Conivaptan 25 mg)	wekhqgurld(ddnzvcdsce) = nnrsxttlrn taoaoonubc (mxlbfnpucw, 4.750) View more
NCT00435591 (CTgov)	Phase 4	Hyponatremia	121	placebo+Conivaptan (Dose Regimen 1)	adijzkpgxd = irebvivqgr eszudlkwzj (ixzmhkhjnu, kggygnjzpv - vvvojjyimj) View more	-	26 May 2010
				Conivaptan (Dose Regimen 2)	adijzkpgxd = mxqgjfnqjw eszudlkwzj (ixzmhkhjnu, srkiryegtj - bhgbhxvyin) View more
NCT00478192 (CTgov)	Phase 3	Hyponatremia	50	Conivaptan (Regimen 1 Conivaptan QD)	ucqtofmxrz(nnmdovxapo) = vsjhsrfzdi kqltqmietk (ornzqzsbdl, 4.017) View more	-	21 Apr 2010
				Conivaptan (Regimen 2 Conivaptan BID)	ucqtofmxrz(nnmdovxapo) = jjnferfayp kqltqmietk (ornzqzsbdl, 3.581) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis